CLINICAL ROLE -
Video
Author(s):
Alexandra S. Wolff, PharmD, BCOP, highlights considerations for optimal use of venetoclax in patients with AML, such as tumor lysis syndrome prophylaxis.
Introducing Obecabtagene Autoleucel: A New Chapter in ALL Treatment
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
Thrombosis May Increase Risk of Cardiovascular Disease, Secondary Cancers in Myeloproliferative Neoplasms
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Momelotinib Shows Strong Efficacy in JAK-Exposed Myelofibrosis Patients
Zanubrutinib Plus Venetoclax and Obinutuzumab Yields Deep Remissions in Patients With Chronic Lymphocytic Leukemia